Coherus, Baxalta's Enbrel biosimilar meets in Phase III

Coherus BioSciences Inc. (NASDAQ:CHRS) and Baxalta Inc. (NYSE:BXLT) said CHS-0214 met the primary 12-week endpoints in a Phase III study to treat plaque psoriasis. CHS-0214 is a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN).

The partners said CHS-0214 demonstrated equivalence to Enbrel on PASI 75 improvements. The compounds had similar safety profiles. ...